Manager Exports
CurrentIn 2019, started the company's export operations from the ground up, simultaneously initiating the introduction of the company's profile to a range of international markets. Took charge of overseeing the export activities for 500+ pharmaceutical products, expanding to 6+ international markets. This strategic move led to a remarkable 36% annual revenue growth over a span of 3 years.• Skillfully secured a contract manufacturing agreement with Kenya's prominent sales and distribution company, marking a successful achievement. Introduced a line of Empagliflozin and Empagliflozin + Metformin products, which in turn led to an impressive 50.77% increase in revenue. This accomplishment not only provided a significant boost to the export department but also empowered it to undertake additional initiatives within the global markets. • Pioneered the introduction and launch of the world's 1st Empagliflozin + Sitagliptin combination within the Kenyan market. • Established yet another joint venture, this time with one of Kenya's major sales and distribution companies for an extensive range of 50+ Oncology products.• Achieved the successful registration and subsequent launch of 10+ products in Kenya, 23+ products in Cambodia, 12+ products in Congo, and an impressive range of 20+ products in Yemen while 6+ products are under registration with Myanmar FDA.• According to the PESA award rankings, elevated the company's pharmaceutical export ranking from beyond 100 to the 72nd position in the 2021 announcement. Furthermore, in the subsequent PESA awards of 2023, the company's ranking further improved to the 56th position.• Conducted explorations and initiatives in various regions including Afghanistan, Francophone countries, Morocco, Myanmar, Sri Lanka, Nepal, Sudan, and Uzbekistan, where the company's manufacturing plant and products are currently in the process of obtaining registrations.